

ASCO® Registry

ASCO Survey on COVID-19 in Oncology (ASCO) Registry
Closing the COVID-19 and Cancer Data Gap

Friday, June 12, 2020



This webcast is supported by educational grants from AstraZeneca Pharmaceuticals, Merck & Co., and Pfizer, Inc.

Participants



**Richard L. Schilsky,
MD, FACP, FSCT, FASCO**
Chief Medical Officer,
Executive Vice President,
American Society of Clinical Oncology



Randall A. Oyer, MD
Medical Director, Oncology Program,
Penn Medicine Lancaster General Health;
2020-21 President,
Association of Community Cancer Centers



Background

- National medical emergency → Opportunity for ASCO to assist the oncology community by gathering information
- Critical need to capture and analyze data on clinical care
 - Analyze distribution of symptoms and severity of COVID-19 among people with cancer
 - Examine impact of COVID-19 on cancer treatment and outcomes
 - Document adaptations of cancer care to the pandemic

Types of Data Collected

Patient Data

- Confirmed COVID-19 Diagnosis and
 - Initiating treatment for new diagnosis
 - Clinically evident cancer receiving anti-cancer treatment
 - Clinically evident cancer receiving supportive care only
 - Disease-free but receiving adjuvant therapy within 1 year after surgical resection

Practice Data

- Number of confirmed COVID-19 cases
- Use of telemedicine
- Modifications of infusions, other treatments
- Screening/triaging processes
- Physical changes to offices
- Drug and PPE shortages
- Staffing changes

Data Collection

- Practice executes research participation & data use agreement with ASCO
- Two data entry options:
 - Submit data to ASCO via web-based REDCap forms
 - ASCO will de-identify data and return data to practice for their own use
 - Collect data locally using “cloned” REDCap project
 - Practices upload data to ASCO at monthly intervals
- ASCO Registry qualifies as High-weighted Practice Improvement Activity under the Merit-based Incentive Payment System (MIPS)
- Agreement and data capture forms can be found online:
 - asco.org/asco-coronavirus-information/coronavirus-registry

Deliverables

- Periodic reports on estimates of disease severity, treatment modifications, and clinical outcomes of patients
 - Data summaries to participating practices
 - Publicly available reports to inform patients and clinicians
- Scientific manuscripts for peer-reviewed publication
- Registry data in ASCO Data Library will be available to qualified researchers

Current Status

- More than 100 practices currently in approval process
- 33 practices in 21 states fully enrolled
- Data on >100 patients already entered
- 80% of practices enrolled are ACCC members – THANK YOU!

Initial Results Regarding Practice Changes

- 20 sites from 17 practices across 15 states
 - 3 academic, 9 hospital/health-system owned, and 5 physician-owned
- 90% reported new use of telemedicine
 - 85% conducted some or all routine visits for patients not in active therapy by telemedicine; 15% delayed some routine visits
- Lab collection: 60% allow collection closer to home
- 40% experienced staffing reductions/changes
 - Due to reassignment, COVID-19, and reduced scheduling of patient visits

THANK YOU

To enroll in the ASCO Registry, visit:
asco.org/asco-coronavirus-information/coronavirus-registry

Questions? Email: CENTRA@asco.org

We Always Want to Do Better for Our Patients

- We are informed by scientific literature
- We are guided by trusted partners, especially ASCO and ACCC
- We know that the most robust information comes from having a strong data set

COVID-19 Hits in a Data-Free Zone: One Community's Approach

- Organized twice weekly COVID-19 Community Oncology Cooperative (COC)
- Four medical oncology practices invited
- Half-hour conference call at 7:00 AM
- Prepared topics and open discussion
- Review of early literature, news reports, and institutional experience

Lancaster COVID-19 COC

- Which cancer patients are at greatest risk?
- What are the complications and outcomes?
- What are the best treatment(s) and management situations?
- What should we do about patients' anti-cancer treatment(s)?
- What should we do in our practices to limit spread?

ASCO Registry

- The data set is in the community
- We need the answers
- It is our opportunity and responsibility to participate

Lancaster General Penn Medicine Experience

- Opening the trial was easy
- IRB exemption
- Research exemption
- Entered first two patients, 15 minutes each
- Follow up is easy
- Staff feel good about participating

Patients Desirous of Participating in Research

- Shared ACCC and ASCO goals
- Bridge the gap between the university and the community
- Be sure that all Americans share equally in advances from cancer research

The Time to Act is NOW

- Please join the ASCO Registry
- We need your collaboration on these urgent scientific questions
- Help us reach as many people as possible

ACCC COVID-19 Resources

acc-cancer.org/COVID-19

- **Weekly Webcast Series**
 - Weathering the COVID-19 Storm: One Program's Care Coordination Experience (Friday, June 19)
 - Green Light for Cancer Research During COVID-19 (Friday, June 26)
- **CANCER BUZZ Mini-Podcasts**
 - COVID-19 vs. Biocontainment; Telemedicine; Drive-Thru COVID-19 Screenings; COVID-19 & Oral Oncolytics; Urban & Rural Cancer Care
- **Evidence-Based Guidelines**
- **Peer-to-Peer Discussions on ACCCeXchange**